Clinical Trial

Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay

Completed
View on ClinicalTrials.gov →
Summary
This is a national-level research study of neurologists and dementia specialists. The purpose of this study is to assess the clinical evaluation and management recommendations made by practicing providers for patient simulations with symptoms of cognitive decline.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-24; most recent amendment 2026-01-05.
Status change: Active, Not Recruiting → Completed 2026-01-05
Status change: Recruiting → Active, Not Recruiting 2025-12-15
Status change: Not Yet Recruiting → Recruiting 2025-08-18
Trial Details
NCT Number NCT07099001
Lead Sponsor Qure Healthcare, LLC
Collaborators: Beckman Coulter, Inc.
Conditions Alzheimer Disease (AD), Cognitive Decline
Enrollment 178 participants
Start Date 2025-08-08
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-07